个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Lu, M.[1] * ; Yu, X.[2] ; Chen, Z.[3] ; Zhang, Y.[4] ; Li, Z.[5] ; Zhang, X.[6] ; Yin, F.[7] ; Ye, F.[8] ; Cheng, Y.[9] ; Song, L.[10] ; Xu, J.[11] ; Zhou, J.[12] ; Shi, H.[12] ; Tan, P.[12] ; Fan, S.[12] ; Su, W.[12] ; Shen, L.[1] ;
机构： [1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis andTranslational Research (Ministry of Education), Peking University Cancer Hospital &Institute, Beijing, China [2]Department of Pancreatic Surgery, Fudan UniversityShanghai Cancer Center, Shanghai, China [3]Department of Medical Oncology, TheSecond Hospital of Anhui Medical University, Heifei, China [4]Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin,China [5]Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China [6]Melanoma and Sarcoma Medical Oncology Unit, State KeyLaboratory of Oncology in South China, Collaborative Innovation Center for CancerMedicine, Sun Yat-sen University Cancer Center, Guangzhou, China [7]Department ofGastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang,China [8]Oncology Department, The First Affiliated Hospital of Xiamen University,Xiamen, China [9]Department of Medical Oncology, Jilin Province Cancer Hospital,Changchun, China [10]Department of Oncology, The First Affiliated Hospital ofZhengzhou University, Zhengzhou, China [11]Department of Medical Oncology, The FifthMedical Center, General Hospital of the People’s Liberation Army, Beijing, China [12]Clinical Development and Regulatory Affairs, HUTCHMED, Shanghai, China
出处：
DOI： 10.1016/j.annonc.2021.10.174
ISSN：
基金：
HUTCHMED
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis andTranslational Research (Ministry of Education), Peking University Cancer Hospital &Institute, Beijing, China
推荐引用方式(GB/T 7714)：
Lu M.,Yu X.,Chen Z.,et al.Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study[J].ANNALS OF ONCOLOGY.2021,32:S1448-S1448.doi:10.1016/j.annonc.2021.10.174.
APA：
Lu, M.,Yu, X.,Chen, Z.,Zhang, Y.,Li, Z....&Shen, L..(2021).Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study.ANNALS OF ONCOLOGY,32,
MLA：
Lu, M.,et al."Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study".ANNALS OF ONCOLOGY 32.(2021):S1448-S1448

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号